Invasive fungal infection (IFI) remains a signi¢cant cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation (alloSCT). Fluconazole (FLU) is widely used as antifungal prophylaxis in patients undergoing alloSCT. In randomized trials, FLU prophylaxis has decreased the incidence of IFIs and reduced the need for amphotericin therapy (1^3). In addition, long-term data have demonstrated a survival advantage for patients receiving FLU versus placebo following bone marrow transplant (3) . However, FLU has a narrow antifungal spectrum and resistant Candida and ¢lamentous mold infections remain problematic. In a recent randomized trial, posaconazole, a second-generation triazole with broadspectrum activity against yeasts and molds, has demonstrated improved e⁄cacy over FLU as prophylaxis for invasive Aspergillus infection in patients with severe graftversus-host disease (GVHD) following alloSCT (4) . Limitations of posaconazole include the lack of an intravenous (IV) formulation and poor bioavailability. Voriconazole (VOR) is another second-generation triazole with improved activity against IFIs including non-albicans Candida and Aspergillus species (5) .VOR is available in both oral and IV formulations, has excellent bioavailability, and consequently is an attractive alternative to FLU and posaconazole for prophylaxis following alloSCT.
Since approval by the US Food and Drug Administration in 2001,VOR has been used as standard antifungal prophylaxis for patients undergoing alloSCT at the University of California, San Francisco (UCSF) Medical Center. In this retrospective review, we report the incidence of early and late IFIs and assess the toxicity of VOR when used as prophylaxis for alloSCT. All patients have been followed for 41 year after alloSCT, with a mean follow-up of 1.83 years.
Material and methods

Patient selection
The study design was a retrospective chart review of consecutive patients undergoing alloSCT at UCSF Medical Center from May 2002 through June 2004. Patients received VOR as antifungal prophylaxis and the frequency of IFI was determined. Seventy-two patients were included in this analysis and no patients were excluded due to early mortality (death within 30 days of alloSCT). All patients signed informed consent for the transplant procedure and approval was obtained for this retrospective analysis from the UCSF institutional review board.
Transplantation and supportive care
Both myeloablative and non-myeloablative conditioning regimens were utilized. Myeloablative therapy consisted of IV busulfan (12.8 mg/kg) or total body irradiation (1200 cGy) with £udarabine (150 mg/m 2 ) or cyclophosphamide (120 mg/kg). Non-myeloablative therapy utilized IV busulfan at a lower dose (4.8^6.4 mg/kg), or melphalan (100 mg/m 2 ) with £udarabine. Anti-thymocyte globulin was added for non-myeloablative alloSCT with unrelated donors. In general, GVHD prophylaxis consisted of tacrolimus (TAC) starting from day À 2 with a target level of 5^15 ng/mL and methotrexate (5 mg/m 2 IV once daily on days 1 1, 1 3, 16, and 1 11). Patients receiving nonmyeloablative unrelated alloSCTalso received mycophenolate mofetil (15 mg/kg twice daily [b.i.d.]) starting from day 0 and continuing until day 160. Most patients received granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells, with a target dose of 5 Â 10 6 /kg recipient weight. Human leukocyte antigen (HLA) typing was performed using high-resolution molecular techniques for unrelated donors and only well-matched donors were utilized (i.e., siblings were fully HLA-matched while unrelated donors were matched at 7/8 or 8/8 HLA-loci [A, B, C, DR] for myeloablative SCT, or 9/10, or 10/10 HLA-loci [A, B, C, DR, and DQ] for non-myeloablative SCT). Stem cell processing was performed for ABO incompatibility according to standard blood banking procedures. By convention, the day of stem cell infusion was considered day 0 of alloSCT.
Patients were hospitalized in single rooms equipped with high-e⁄ciency particulate air (HEPA) ¢lter systems. Infectious disease prophylaxis included oral antibacterials (levo£oxacin or moxi£oxacin) during neutropenia, oral or IV antivirals starting from day À 2 (acyclovir), and prophylaxis for Pneumocystis jirovecii pneumonia following engraftment (i.e., trimethoprim/sulfamethoxazole or dapsone). Oral VOR 4 mg/kg b.i.d. started from day À 2 and continued until immunosuppression was discontinued (4100 days).Weight-based VOR dosing was chosen to limit intra-patient variability and in an attempt to improve therapeutic drug delivery. Broad-spectrum IV antibiotics were used for episodes of febrile neutropenia. Preemptive monitoring of cytomegalovirus (CMV) infection (weekly CMV blood antigen) was used for patients who were at risk for CMV reactivation. G-CSF was given to all patients starting at day 17 and continued until absolute neutrophil count 41500/mL for 2 consecutive days. Corticosteroids were used as ¢rst-line therapy for acute and chronic GVHD.
Evaluations and de¢nitions
The primary objective of the study was to evaluate the incidence of early and late IFI using VOR as prophylaxis for alloSCT. IFI was evaluated according to EORTC-de¢ned criteria ( Fig. 1 ) (6). Brie£y, de¢nite IFI was de¢ned as a fungal pathogen isolated by culture or identi¢ed by histology from a known sterile site (i.e., biopsy-proven disease); probable IFI included episodes with clinical evidence of disease (abnormal chest x-ray) and positive culture from the site (e.g., bronchoalveolar lavage, sputum) or positive galactomannan assay. Possible IFI included episodes with an abnormal radiology study plus 2 or more abnormal host factors (e.g., fever, sputum, cough) but no positive cultures. Plasma VOR drug levels and galactomannan assays were not routinely performed. Early IFI was de¢ned as that Definite IFI: histopathologic or cytopathologic evidence of hyphae or yeast, or positive culture result on sample obtaind by sterile procedure from a normally sterile and clinically or radiologically abnormal site consistent with infection.
Probable IFI: one host factor (i.e., persistent fever, prolonged neutropenia, steroid use, graft-versus-host disease) AND one microbiologic criteria (i.e., positive culture of sputum / broncho-alveolar lavage or positive serum galactomannan antigen assay) AND one major (classic computerized tomography finding) or two minor clinical criteria (e.g., cough, hemoptysis, pleural rub, new infiltrate).
Possible IFI: one host factor AND one microbiologic criteria or one major/two minor clinical criteria . occurring within 120 days of alloSCT, with late IFI occurring after day 120. All microbiologic and radiographic data for each patient were reviewed.
Secondary outcomes assessed were incidence of non-fungal infections, incidence of acute/chronic GVHD, VOR-related toxicity, treatment-related mortality, disease-free survival, and overall survival. Treatment-related mortality was de¢ned as any non-disease-associated death occurring within 120 days of alloSCT.
Results
Subjects had a wide variety of malignant disease (Table 1 ). Approximately half of the patients received non-myeloablative conditioning and a slight majority of patients received stem cells from sibling donors. In general, most patients were considered high-risk because of adverse cytogenetics, prior disease relapse, or failure of prior autologous transplantation. The mean follow-up for survivors is 668 days (1.83 years, range 0.10^4.23 years) after alloSCT.
Primary endpoint
Seventy-two patients were evaluated for early IFI and only 2 developed de¢nite IFI (Table 2) . One patient developed IFI following severe GVHD requiring treatment with more than 3 immunosuppressive agents. This patient was hospitalized continuously post alloSCT and died of IFI with active GVHD at approximately day 1 100 post alloSCT. Disseminated mucormycosis infection was identi¢ed at autopsy.The second patient developed veno-occlusive disease within 25 days following alloSCT and discontinued VOR because of elevated total bilirubin at approximately day 30 post transplant. This patient subsequently received an echinocandin for antifungal prophylaxis and developed IFI with Aspergillus and Scedosporium proli¢cans. The patient died of IFI at approximately day 80 post alloSCT.
No cases of probable IFI were identi¢ed and 6 cases of possible IFI occurred. Five of the patients with possible IFI responded to either broad-spectrum antibiotics or the addition of an echinocandin to VOR therapy. One patient died rapidly from pneumonia and culture-negative sepsis, presumably of bacterial origin. In general, all patients with possible IFI were more likely to have viral or bacterial etiologies for their infections.
Sixty-four patients survived longer than 120 days post transplantation and thus were evaluable for incidence of late IFI. Late IFI developed only in patients who had chronic GVHD, or who were on steroids for other reasons (relapse, possible autoimmune cytopenia). Two patients developed de¢nite IFI (both Aspergillus) and both died of progressive infection. Both patients had been o¡ VOR for several months before development of IFI (1 due to hyperbilirubinemia, 1 who was non-adherent with VOR prophylaxis despite chronic GVHD). The 4 patients experiencing late probable IFI also were already o¡ VOR at the time of 
Secondary endpoints
VOR was well tolerated. Ten patients (14%) stopped VOR because of drug toxicity.The reasons for stopping included elevated liver function tests (LFT) in 6 patients, veno-occlusive disease in 2 patients, toxic TAC level in 1 patient, and prolonged cardiac corrected Q-T interval (QTc) (4500 msec) in 1 patient. Four patients were able to restart VOR when their LFT abnormalities improved. Of note, VOR increased serum TAC levels in all patients, necessitating a 60% reduction in standard TAC dosing. Despite a low incidence of fungal disease, bacterial and viral infections were common ( Table 3 ). The incidence of CMV reactivation was approximately 28% and gram-positive bacteremia was 24% in the early post-transplant period. Late post-transplant gram-positive bacteremia was seen in 35% of patients and late CMV re-activation occurred in approximately 10% of patients. Clostridium di⁄cile infections were detected in 11/72 (15%) of early patients and 7/64 (11%) of late patients, and was more prevalent than expected.
The incidence of acute and chronic GVHD was 34% and 61%, respectively (Table 4) . Severe (Grades III^IV) acute GVHD was seen in 11% of patients. Treatment-related mortality within the ¢rst 120 days of transplant was 11% and within the ¢rst year was 21%. Approximately 6% of patients died of GVHD and 14% died directly due to infection (3% IFI, 11% bacterial infection). The 2-year progressionfree survival and overall survival rates in this high-risk population were 38% and 47%, respectively (Fig. 2) . Disease relapse was the most common cause of death (19 patients; 30%).
Discussion
The main focus of this retrospective review was to evaluate the safety and e⁄cacy of VOR as prophylaxis for IFI following alloSCT. Epidemiology studies suggest that there is a Martin et al: Voriconazole as prophylaxis for IFI in alloSCT bimodal incidence of IFI following alloSCT (7, 8) .The initial peak incidence is during marrow aplasia, when neutropenia is severe and barrier breakdown is present (day o40). Although mold infections predominate, Candida infections also occur. The second peak occurs following day 40 but usually 4day 100 with the development of chronic GVHD. Invasive mold and Candida infections occur.The incidence of early IFI has been reported to be approximately 4% (7 ). The incidence of late fungal infection is not well reported but generally believed to occur in an additional 101 5% of patients surviving 4120 days post alloSCT (9, 10). Our data suggest that antifungal prophylaxis with VOR in the setting of alloSCT is both safe and e¡ective. Only 2 of 72 patients developed early IFI (1 while on VOR), an acceptable rate (2.8%) of IFI (meets 95% con¢dence interval [CI] assuming an expected IFI rate of 4% [CI 1.88^2.88]). This low incidence of early mold infection con¢rms 2 prior studies of VOR prophylaxis in alloSCT reported by Siwek et al. (11) and Tri¢lio et al. (12) . Both studies reported a low incidence of mold infections but a higher incidence of breakthrough Candida and zygomycosis infections. The Tri¢lio study limited VOR prophylaxis to high-risk alloSCT patients (i.e., those taking corticosteroids or with active GVHD). Overall, they reported 6 invasive Candida infections (incidence 10%), with Candida glabrata being the most common isolate. Of note, C. glabrata has a high minimum inhibitory concentration for 90% of organisms ( $ 1 mcg/mL) with VOR, and several patients in the study had low serumVOR levels. The study used oral VOR dosing of 200 mg b.i.d. and the authors subsequently identi¢ed plasma concentrations of VOR o2 mcg/mL as a risk factor for IFI, especially Candida. In our study, the mean oralVOR dose was 300 mg b.i.d. It is well established that plasma concentrations are exponentially correlated to dose, thereby an increase fromVOR 200 to 300 mg b.i.d. is expected to increase plasma VOR concentrations by 42.5 -fold. Therefore, it is possible that the weight-based VOR dosing of 4 mg/kg b.i.d. may have been responsible for the low breakthrough (C. glabrata) infections in this report. These data suggest that measuring and optimizing VOR levels may have therapeutic consequence in preventing breakthrough IFI in immunocompromised alloSCT patients. A prospective trial investigating targeted blood levels and doseadjusted VOR in high-risk alloSCT patients is warranted.
Many studies have raised concern about an increased incidence of zygomycosis infections following use of VOR in alloSCT (13^15). However, the data are still limited, and no conclusions can be made. One theory is that better supportive care, treatments such as VOR, and the use of more potent immunosuppression allow prolonged survival of severely immunocompromised patients, thus giving more time for resistant fungal infections to develop. This retrospective study does not support an increased incidence of zygomycosis. Only a large prospective randomized trial can con¢rm the association of VOR to zygomycosis infection.
There is no standard antifungal prophylaxis for patients experiencing chronic GVHD (cGVHD) and no published reports on VOR prophylaxis during cGVHD. In this report, a total of 6 of 39 patients developed late de¢nite or probable IFI, but none of these patients developed fungal disease while on VOR. The majority of subjects developed GVHD following tapering of their immunosuppression and after discontinuing VOR. As expected, cGVHD was present before the development of late IFI in most patients, although the initiation of corticosteroids for other reasons (disease relapse, possible autoimmune cytopenia) was an important factor for IFI in 2 patients. A multivariate analysis was performed but failed to identify signi¢cant risk factors for late IFI, likely owing to the low incidence of disease. Overall, these data suggest that VOR is e¡ective prophylaxis for preventing late IFI in patients with cGVHD receiving intensive immunosuppression. As mold infections are a signi¢cant cause of late morbidity and mortality in those with cGVHD, studies are warranted to better de¢ne optimal antifungal therapy during cGVHD (10) .
In this cohort of patients, VOR was administered post transplant for a median time of 128 days and was well tolerated. Common side e¡ects of VOR included visual disturbances and liver enzyme elevations. In 3 patients, the abnormal liver tests occurred a mean of 8 days post transplant and this was likely due to preparative therapy toxicity. Three other patients discontinued VOR because of liver test abnormalities a mean of 81 days post transplant and all had possible GVHD. Overall, the side e¡ects fromVOR were not prohibitive and could be managed with dose interruptions and/or dose reductions. VOR administration was strictly prohibited during chemotherapy because of predictable drug^drug interactions. In addition, a 60% reduction in TAC dosing was required, thus o¡setting some of the costs associated with VOR dosing.
In conclusion, VOR prophylaxis in alloSCT is safe and e¡ective at preventing early and late IFI. Evaluating VOR levels and optimizing VOR dosing may help to prevent breakthrough fungal infection. LFTs and the QTc should be monitored in patients receiving VOR as dose adjustments may be required. The low incidence of zygomycosis infections in this study does not support the premise that VOR usage increases the incidence of resistant IFI. Although most centers continue to use FLU as antifungal prophylaxis,VOR usage should be considered in centers where the incidence of mold infection is increased. A randomized clinical trial of FLU versus VOR prophylaxis in alloSCT is ongoing and should further clarify the role of VOR as prophylaxis (http://clinicaltrials.gov/ct/show/NCT00023530? order=1). A randomized trial of VOR versus posaconazole prophylaxis in alloSCT would also be of value.
